open access
Elevated serum NSE level in locally advanced and metastatic NSCLC predispose to better response to chemotherapy but worse survival
open access
Abstract
Abstract
Keywords
neuron specific enolase; non-small-cell lung cancer; prognosis; response to treatment


Title
Elevated serum NSE level in locally advanced and metastatic NSCLC predispose to better response to chemotherapy but worse survival
Journal
Advances in Respiratory Medicine
Issue
Article type
Research paper
Pages
14-20
Published online
2010-01-29
Bibliographic record
Pneumonol Alergol Pol 2010;78(1):14-20.
Keywords
neuron specific enolase
non-small-cell lung cancer
prognosis
response to treatment
Authors
Monika Załęska
Monika Szturmowicz
Jacek Zych
Barbara Roszkowska-Śliż
Urszula Demkow
Renata Langfort
Kazimierz Roszkowski-Śliż


- Barlési F, Gimenez C, Torre JP, et al. Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer. Respir Med. 2004; 98(4): 357–362.
- Ebert W, Dienemann H, Fateh-Moghadam A, et al. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study. Eur J Clin Chem Clin Biochem. 1994; 32(3): 189–199.
- Ferrigno D, Buccheri G, Biggi A. Serum tumour markers in lung cancer: history, biology and clinical applications. Eur Respir J. 1994; 7(1): 186–197.
- Ferrigno D, Buccheri G, Giordano C. Neuron-specific enolase is an effective tumour marker in non-small cell lung cancer (NSCLC). Lung Cancer. 2003; 41(3): 311–320.
- van Zandwijk N, Jassem E, Bonfrer JM, et al. Serum neuron-specific enolase and lactate dehydrogenase as predictors of response to chemotherapy and survival in non-small cell lung cancer. Semin Oncol. 1992; 19(1 Suppl 2): 37–43.
- Zych J, Szturmowicz M, Sakowicz A, et al. [Neuron-specific enolase (NSE) serum level as a prognostic factor in non-small cell lung cancer]. Pneumonol Alergol Pol. 2002; 70(5-6): 278–283.
- World Health Organization.. Histological typing of lung cancer tumors. In: International classification of tumors. 2 nd ed. WHO, Geneva 1981.
- Reif PT, Rivera MP. Evidence-base outcomes for patients with advanced non-small cell leng cancer. Semin. Respir. Crit. Care Med. 2000; 21: 1–16.
- Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest. 1997; 111(6): 1710–1717.
- Moran CA, Suster S, Coppola D, et al. Neuroendocrine carcinomas of the lung: a critical analysis. Am J Clin Pathol. 2009; 131(2): 206–221.
- Carles J, Rosell R, Ariza A, et al. Neuroendocrine differentiation as a prognostic factor in non-small cell lung cancer. Lung Cancer. 1993; 10(3-4): 209–219.
- Sundaresan V, Reeve JG, Stenning S, et al. Neuroendocrine differentiation and clinical behaviour in non-small cell lung tumours. Br J Cancer. 1991; 64(2): 333–338.
- Linnoila RI, Piantadosi S, Ruckdeschel JC. Impact of neuroendocrine differentiation in non-small cell lung cancer. The LCSG experience. Chest. 1994; 106(6 Suppl): 367S–371S.
- Graziano SL, Tatum AH, Newman NB, et al. The prognostic significance of neuroendocrine markers and carcinoembryonic antigen in patients with resected stage I and II non-small cell lung cancer. Cancer Res. 1994; 54(11): 2908–2913.
- Slodkowska J, Zych J, Szturmowicz M, et al. Neuroendocrine phenotype of non-small cell lung carcinoma: immunohistological evaluation and biochemical study. Int J Biol Markers. 2005; 20(4): 217–226.
- Pelosi G, Pasini F, Sonzogni A, et al. Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma. Cancer. 2003; 97(10): 2487–2497.
- Hiroshima K, Iyoda A, Shibuya K, et al. Prognostic significance of neuroendocrine differentiation in adenocarcinoma of the lung. Ann Thorac Surg. 2002; 73(6): 1732–1735.
- Ruibal A, Nuñez MI, Rodríguez J, et al. Cytosolic levels of neuron-specific enolase in squamous cell carcinomas of the lung. Int J Biol Markers. 2003; 18(3): 188–194.
- Nisman B, Heching N, Biran H, et al. The prognostic significance of circulating neuroendocrine markers chromogranin a, pro-gastrin-releasing peptide and neuron-specific enolase in patients with advanced non-small-cell lung cancer. Tumour Biol. 2006; 27(1): 8–16.
- Pujol JL, Boher JM, Grenier J, et al. Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients. Lung Cancer. 2001; 31(2-3): 221–231.
- Maeda T, Ueoka H, Tabata M, et al. Prognostic factors in advanced non-small cell lung cancer: elevated serum levels of neuron specific enolase indicate poor prognosis. Jpn J Clin Oncol. 2000; 30(12): 534–541.
- Akerley W, Crowley J, Giroux D, et al. Response to chemotherapy as a predictor of survival in advanced non-small cell lung cancer (NSCLC): Review of the Southwest Oncology Group (SWOG) database. Lung Cancer. 2000; 29(1): 33.
- Betticher DC, Hsu Schmitz SF, Tötsch M, et al. Swiss Group for Clinical Cancer Research (SAKK). Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. Br J Cancer. 2006; 94(8): 1099–1106.
- Johnson K, Ringland C, Stokes B, et al. Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. The Lancet Oncology. 2006; 7(9): 741–746.
- Diez M, Torres A, Ortega L, et al. Value of serum neuron-specific enolase in nonsmall cell lung cancer. Oncology. 1993; 50(2): 127–131.
- Hatzakis KD, Froudarakis ME, Bouros D, et al. Prognostic value of serum tumor markers in patients with lung cancer. Respiration. 2002; 69(1): 25–29.
- Foa P, Fornier M, Miceli R, et al. Preoperative CEA, NSE, SCC, TPA and CYFRA 21.1 serum levels as prognostic indicators in resected non-small cell lung cancer. Int J Biol Markers. 1999; 14(2): 92–98.
- Reinmuth N, Brandt B, Semik M, et al. Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer. Lung Cancer. 2002; 36(3): 265–270.